Lidocaine Iv + Placebo
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Trial Timeline
Jan 1, 2024 → Jun 1, 2025
NCT ID
NCT04614610About Lidocaine Iv + Placebo
Lidocaine Iv + Placebo is a phase 2 stage product being developed by Johnson & Johnson for Sickle Cell Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT04614610. Target conditions include Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04614610 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Sickle Cell Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prasugrel + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 33 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel | Daiichi Sankyo | Phase 2 | 52 |
| Lexiscan | Astellas Pharma | Phase 1 | 33 |
| Placebo + Dalteparin | Eisai | Phase 2 | 52 |
| tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT]) | Eli Lilly | Phase 1 | 33 |
| ICA-17043 | Johnson & Johnson | Phase 3 | 77 |
| Ticagrelor | AstraZeneca | Phase 1 | 33 |
| Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet) | AstraZeneca | Phase 1 | 33 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Ticagrelor + Placebo | AstraZeneca | Phase 3 | 77 |
| Brilinta + Placebo | AstraZeneca | Phase 3 | 77 |
| Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b | AstraZeneca | Phase 2 | 52 |
| vorinostat | Merck | Phase 2 | 52 |
| Crizanlizumab + Placebo | Novartis | Phase 3 | 77 |
| Crizanlizuamb + Standard of Care | Novartis | Phase 2 | 52 |
| Crizanlizumab | Novartis | Approved | 85 |
| Hydroxyurea | Novartis | Phase 3 | 77 |